Zimmer Biomet Holdings ( (ZBH) ) has realeased its Q3 earnings. Here is a breakdown of the information Zimmer Biomet Holdings presented to its investors.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Zimmer Biomet Holdings, Inc. is a global leader in medical technology that specializes in creating solutions for improving mobility and overall health, leveraging advanced digital and robotic technologies to enhance patient care.
In its recent earnings report for the third quarter of 2024, Zimmer Biomet reported net sales of $1.824 billion, reflecting a growth of 4.0% compared to the previous year. The company’s adjusted earnings per share stood at $1.74, showcasing resilience despite challenges posed by ERP implementation issues.
Key financial highlights include a robust performance in international markets, with sales growing by 6.9% and notable category growth in knees and hips. Strategically, the company announced the commercial launch of the Z1 Femoral Hip System and the acquisition of OrthoGrid Systems Inc., expanding its portfolio in AI-driven surgical guidance systems. The company has also narrowed its full-year financial guidance, adjusting its revenue growth expectations slightly downward.
Looking ahead, Zimmer Biomet remains focused on its strategic priorities to drive innovation and product introductions, aiming to address global unmet medical needs while navigating operational challenges with a commitment to enhancing patient outcomes.
